未找到相关数据
Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy
被引：8
作者：
Archer, V.
Reck, M.
Sandler, A. B.
Johnson, D. H.
Kong, G.
Strickland, D. K.
Bennouna, J.
机构：
[1] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[2] Krankenhaus Grosshansdorf, Grosshansdorf, Germany
[3] Vanderbilt Univ, Nashville, TN USA
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Ctr Rene Gauducheau, St Herblain, France
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8114
引用
收藏
页数：1
相关论文